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Highlights 
 A randomized control trial of two types of PICC lines on the outcomes is described.
 No difference was noted in outcomes among the two types of PICC lines.
 Larger randomized control trials should be conducted to test these results.
Abstract 
INTRODUCTION: Central line associated blood stream infections (CLABSIs) are a common 
life‐threatening risk factor associated with central venous catheters (CVCS). Research has 
demonstrated benefit in reducing CLABSI’s when CVC’s coated with antimicrobials are 
inserted. The impact of chlorhexidine (CHG) impregnated versus non‐CHG PICCs on risk of 
CLABSI is unknown. Venous thromboembolism (VTE) is also a complication associated with 
CVCs. This study compares the impact of both PICC lines on these outcomes. 
METHODS: Patients in 3 high risk units were randomly assigned to receive either a CHG 
impregnated or non‐CHG PICC line. Laboratory data was collected and reviewed daily on all 
study patients. The PICC dressing site was assessed daily. Medical record documentation 
was reviewed to determine presence of CLABSI and/or VTE. 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as:
Storey, S., Brown, J., Foley, A., Newkirk, E., Powers, J., Barger, J., & Paige, K. (2016). A comparative evaluation of antimicrobial 
coated versus nonantimicrobial coated peripherally inserted central catheters on associated outcomes: A randomized controlled trial. 
American Journal of Infection Control, 44(6), 636–641. https://doi.org/10.1016/j.ajic.2015.11.017
2 
RESULTS: 167 patients completed the study. Three patients developed CLABSI (2 in the CHG 
and 1 non‐CHG) and 3 patients developed VTE (2 in the non‐CHG and 1 in the CHG PICC. No 
significant relationship was noted between the type of PICC line on development of a 
CLABSI (p = .61) or VTE (p = 1.00). A significant difference was noted in moderate bleeding 
(p = < .001) requiring thrombogenic dressing in the patients who had the CHG PICC line.  
CONCLUSION: No differences were noted in the development of CLABSI and VTE between 
the CHG and non‐CHG groups.  
Central venous catheters (CVCs) are important in the medical management of acutely ill 
patients. The most common and life-threatening complication of CVCs is the risk for a central 
line associated related blood stream infection (CLABSI). CLABSIs are preventable and when 
they occur during hospitalization, they are considered to be a hospital acquired infection (HAI). 
Subsequently, they impact patient outcomes and reimbursement of hospitalization costs from the 
Centers for Medicare and Medicaid Services, as well as private insurance companies. It is 
estimated in the United States (U.S.) that 1 of 20 hospitalized patients will develop a HAI.1 
CLABSIs are the third leading cause of HAIs, following catheter associated urinary tract 
infections and surgical site infections.2 
According to the Joint Commission (2012), 3 million central lines are used each year.3 It 
is estimated that 41,000 CLABSIs occur in U.S. hospitals each year with approximately 18,000 
occurring in the intensive care unit (ICU) and 23,000 in non-ICU populations.3  CLABSIs are 
costly and associated with poor patient outcomes such as increased length of stay, hospital costs 
and mortality.4,5  It is estimated that CLABSI’s cost the healthcare system approximately $16,550 
per episode,6 and are associated with a mortality rate of 15-25%.7 Reducing CLABSIs is a 
priority for improving patient safety and reducing healthcare costs. 
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Peripherally inserted central catheters (PICCs) are CVCs inserted, via ultrasonographic 
technique, into the upper veins of the arm with the tip advanced to the superior vena cava. PICC 
lines provide intravenous access for the administration of parenteral fluids, medications, blood 
products and nutrition as well as providing venous access for phlebotomy. PICC lines are a 
commonly used CVC, especially for patients requiring longer-term intravenous access. As with 
all CVCs, CLABSI is a potential risk in patients with PICC lines.  Risk factors for the 
development of CLABSI include the number of times the line is manipulated, location of 
insertion,8 and prolonged dwell time,9, 10 and the development of thrombus.11Trauma and critical 
care patients, as well as those admitted with immune suppression are at an increased risk for 
CLABSI.12,13 
In addition to the risk of CLABSI associated with PICC lines, upper extremity venous 
thromboembolism (VTE) is another potential complication.14, 15  One study found 5% of 
hospitalized patients develop a symptomatic upper extremity VTE post PICC line insertion.16 
VTEs related to PICC lines present a challenge in clinical practice as it may interrupt and/or 
delay the patient’s medical treatment plan. Factors associated with the development of VTE 
include catheter size, vein selection,14 and number of insertion attempts.17 In addition, 
researchers acknowledge there may be a reciprocal relationship where infection promotes 
thrombus formation or the presence of thrombus may facilitate the development of an 
infection.15,18 Increased morbidity, hospital costs and length of stay have been associated with 
PICC related CLABSI and VTE.4, 5 
One of the most important aspects in the prevention of CLABSIs is the care and 
maintenance of the line. Evidence-based bundles for insertion and maintenance care have been 
developed to prevent CLABSIs. These include insertion techniques such as: maximum sterile 
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barriers, site preparation and disinfection using chlorhexidine (CHG), sterile insertion procedures 
(mask, gown and gloves) and avoidance of femoral site selection.3 In addition to these 
interventions, the use of antimicrobial or antimicrobial impregnated catheters has been 
recommended if there is no change in CLABSI rate after the implementation of evidence-based 
bundles13 Research has demonstrated significant benefit in reducing CLABSIs when 
antimicrobial (chlorhexidine/silver sulfadiazine) or antibiotic (minocycline/rifampin) CVC’s are 
inserted. A meta-analysis of randomized control trials (RCTs), demonstrated antimicrobial 
impregnated CVC’s were associated with a decrease in bacterial colonization and CLABSI.19  
However, the majority of the studies included in the meta-analysis, focused on CVCs located in 
the femoral, subclavian and jugular veins. There is a paucity of research related to the impact of 
antimicrobial impregnated PICC lines, on the development of CLABSIs and/or VTE.  
In 2011, the United States Food and Drug Administration approved PICC line 
impregnated with chlorhexidine (CHG) was introduced with clearance as a device with 
antimicrobial and anti-thrombogenic protection demonstrated for a minimum of 30 days.20  
Although this device does not contain heparin, it has been shown to have anti-thrombogenic 
properties. 20 Two publications 21, 22 noted decreases in CLABSI rates when the CHG 
impregnated antimicrobial PICC line was utilized, but did not examine its impact on the 
development of VTE. One of the publications described the findings from a quasi-experimental 
study, while the other was a 2-year product evaluation.21, 22 To our knowledge, no RCTs have 
been conducted to examine the impact of CHG PICC lines. Therefore, the purpose of this study 
was to compare an antimicrobial PICC line impregnated with CHG to a non-CHG impregnated 
PICC line on the development of CLABSI and/or VTE among high risk hospitalized patients in 
the cardiovascular thoracic, medical intensive care (MICU) and oncology units. 
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METHOD 
Study Setting and Design 
 This study was conducted over 18 months at a large, 800 bed tertiary community hospital 
in the Midwest. The study was approved by the hospital’s Institutional Review Board. To reduce 
the potential for bias, both the CHG and non-CHG PICC lines were purchased by the institution. 
Three units were chosen for study recruitment due to higher CLABSI rates than other units in the 
hospital.  Patients were enrolled in the study if they met the following inclusion criteria: a) 
required PICC line insertion on the cardiovascular thoracic, cardiovascular thoracic, MICU or 
oncology units; b) inpatient ≥ 18 years of age; c) no allergy to CHG; d) required insertion of a 
single or double lumen PICC line (the study PICC did not have a triple lumen option); e) 
anticipated hospital length of stay > 48 hours. Patients were excluded from the study for: a) 
pregnancy and b) difficult PICC insertion requiring placement in vascular lab. Patients were 
notified upon consent that if their hospital length of stay or duration of the PICC line was in less 
than 48 hours they would be excluded from the study.  
Sample 
Convenience sampling was utilized along with stratified sampling to ensure an equal 
number of participants came from each of the 3 designated study units. Target enrollment was set 
at 60 subjects (30 subjects in the control group and 30 subjects in the standard of care group) 
from each of the 3 units for a total of 180 subjects. To reduce bias, randomization was conducted 
by a third party who randomly mixed and selected envelopes containing study assignment group 
for each unit. Sixty envelopes per unit were divided evenly (30 in each group) and randomly 
assigned to either group A (CHG PICC) or B (non-CHG). The randomized envelope(s) were 
selected and placed in the enrollment folder.  
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Procedures 
After informed consent was obtained, patients were randomly assigned to receive either 
the CHG impregnated antimicrobial PICC or the non-CHG PICC . The non-CHG PICC was the 
standard of care at the facility at the time of the study. Both PICC lines were power-injectable.  
The PICC lines were inserted by the hospital’s specially trained PICC team. There are 
specific differences in the insertion technique between the two types of PICC lines. To ensure 
competency and consistency in placement, all PICC team members completed training on the 
insertion of the CHG impregnated antimicrobial PICC prior to study initiation. Standard 
procedures were followed for insertion of both types of PICC lines. Post-insertion, the PICC 
team documented type of PICC placed (CHG or non-CHG), catheter size, number of lumens, 
insertion date, time and initials of PICC team member responsible for insertion. The PICC team 
also documented post-insertion location, amount and extent of post insertion bleeding and if 
application of thrombogenic dressing or pressure dressing was required.  
Data Collection 
Demographic information was collected at the time of enrollment and included: gender, 
age, unit location and duration of PICC line. The type of PICC line (CHG or non-CHG), 
insertion location and number of catheter lumens were also collected. Daily inspection of the 
PICC dressing and site was conducted by a study investigator to assess for signs and symptoms 
of infection and VTE. The assessment for infection included daily observation and 
documentation of dressing integrity and appearance of insertion site for presence of redness, 
warmth, edema, purulent drainage, and bleeding. To control for variations in technique, patients 
in the study had PICC dressing changes completed by the PICC team nurses or study 
investigators. PICC team nurses and study investigators attended a training review session with 
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return demonstration to assure standard practice and competency in dressing change techniques 
prior to study initiation.  
Medical information on diagnosis, co-morbidities, laboratory and diagnostic tests results 
were collected on study subjects who developed a CLABSI or VTE, the outcomes of interest. 
When available, complete blood counts, specifically white blood cell, absolute neutrophil count 
(ANC), and platelets were reviewed to assess immune status and risk for bleeding in subjects 
who developed CLABSI or VTE. Laboratory-confirmed CLABSIs not secondary to an infection 
at another body site, were reviewed and verified by one certified infection prevention specialists 
based on the criteria established in the Center for Disease Control (CDC) guidelines (CDC, 
2015). The laboratory identified the organism from the culture was also recorded. All patients 
were tracked for development of venous thromboembolism (VTE) in the upper extremity where 
the PICC line was placed. Venous thromboembolism was identified through clinical assessment 
of symptoms and diagnostic tests as ordered per standard practice for suspected occurrence. Post-
insertion bleeding was defined as either moderate or severe dependent on the type of dressing 
required to control the bleeding. Moderate bleeding was defined as the need for application of a 
thrombogenic dressing. Severe bleeding was defined as bleeding that could not be controlled 
with the use of a thrombogenic dressing and required the application of a pressure dressing. 
Statistical Analysis   
An a priori sample size calculation was conducted using the average CLASI infection 
rate for the three selected units, a power of .80, and an alpha level of .05. Based on these 
numbers, a minimum sample size of 60 patients per unit (30 control and 30 experimental) was 
needed. Data were analyzed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., 
Armonk, NY). All tests were two-tailed and an alpha level of < .05 was considered statistically 
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significant. Descriptive statistics were used to describe the sample. Data were checked for 
normality using the Shapiro-Wilk test. The Mann Whitney U test was used to assess differences 
in patient age and duration of PICC lines. Fisher’s exact tests were used to assess for associations 
between the groups for the following outcomes: CLABSI, VTE and severity of post insertion 
bleeding. In addition, a Fisher’s exact test was used to determine if there was a significant 
difference in the post insertion bleeding rate between the three hospital units. 
RESULTS 
Sample characteristics 
One hundred eighty-nine subjects consented for participation and one hundred sixty 
seven completed the study. Twenty-two patients were withdrawn from the study, most due to not 
meeting the inclusion criteria of being hospitalized for at least 48 hours. See Figure 1 for the 
study flow diagram. The majority of study subjects were male. The majority of PICC lines 
placed in the study subjects were 5- French, double lumen, and placed in the basilic vein. No 
statistically significant differences were noted in the demographic or participant characteristics 
between the two groups. See Table 1. The study was discontinued after 18 months because of 
slow enrollment from the cardiovascular thoracic unit due to the frequent need for triple lumen 
PICC placement in which at the time of the study was not available in CHG PICC product line.   
Central line associated bloodstream infection 
Results demonstrated no significant difference between the type of PICC line and the 
development of infection (Table 2). Three patients developed a CLABSI, two from the CHG 
group and one from the non-CHG group. The medical diagnoses of these subjects were: 
lymphoma (n = 1) and acute myeloid leukemia (n = 2). The median duration of the PICC lines 
prior to CLABSI in these three subjects was 18 days. The median number of days the three 
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subjects were neutropenic, defined as an absolute neutrophil count (ANC) < 500 cells/mm2, was 
19. Organisms identified in these CLABSI’s were Klebsiella pneumoniae, Streptococcus 
viridans and Kocuria species (gram + cocci).  
Venous thromboembolism 
Results demonstrated no significant relationship between the type of PICC line and the 
development of VTE (Table 2). Three subjects developed VTE, one in the CHG group and two 
in the non-CHG group. All of the patients who developed VTE were in the MICU. The medical 
diagnoses for the three subjects were ischemic bowel disease, ovarian cancer and hypotension. 
The median duration of the PICC lines prior to the development of VTE was 5 days. All of the 
study subjects had double lumen, 5 French catheter size PICC lines inserted. The subjects that 
developed VTE, all had the PICC lines inserted in the basilic vein (2 in the right and 1 in the 
left). Post-insertion bleeding 
The majority (96%) who had post insertion bleeding were in the CHG PICC group. 
Subjects with the CHG PICC experienced moderate bleeding requiring application of a 
thrombogenic dressing more often compared to those with the non-CHG PICC line. (Table 2). 
No difference in post-insertion bleeding was noted among the 3 units (p = .97). 
Severe bleeding requiring the application of a pressure dressing occurred more often in 
subjects with the CHG PICC. Six of the subjects experienced severe post insertion bleeding 
requiring application of a pressure dressing. Of those, 5 (83%) of the subjects had the CHG PICC 
line.  
DISCUSSION 
Central line associated bloodstream infection 
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In this sample, no difference was noted in the development of CLABSI between the non-
CHG and CHG PICC line study groups. Three patients from the oncology unit developed a 
CLABSI. Oncology patients present a unique challenge as they frequently experience immune 
suppression (neutropenia) as a result of treatment, leaving them vulnerable to infection.12 
Patients with hematologic cancers are susceptible to more days of neutropenia and subsequent 
infections.23 Although this patient population has an increased risk of CLABSI, in this study 
other subjects with these hematologic diagnoses and similar characteristics were randomized to 
both types of PICC lines and did not develop CLABSI. Suggesting as others have noted, that the 
care and maintenance of the PICC line may impact the development of CLABSI perhaps more 
than the type of PICC line used.4 
Other studies noted findings contrary to the findings of this study.  In a quasi-
experimental study of 260 patients receiving the CHG PICC (intervention) compared to 257 
patients who received the non-CHG PICC (historical control), the authors noted those with the 
CHG PICC line had less CLABSIs than those with the non-CHG PICC line (p = .013). 21 These 
findings however, need to be interpreted taking into consideration that this type of study design 
is less rigorous than an RCT and is more susceptible to bias. Additionally, the findings may have 
been influenced by differences in the patient population and/or changes in management of 
patients between the two time periods.  
A quality improvement project conducted over a 2 year period, evaluated the CHG PICC 
line in 100 patients at a long-term acute care hospital. The authors reported no patients developed 
a CLABSI during the evaluation time period.22  Quality improvement initiatives, while 
important, cannot be considered a robust research design and the findings must be interpreted 
with caution. 
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Venous thromboembolism (VTE) 
 The 3 subjects who developed a PICC line associated VTE were from the MICU and had 
5 French PICC lines inserted in the basilic vein.  In other studies, VTE has been shown to be 
associated with catheter size; specifically researchers have shown the risk increases with catheter 
sizes ≥ 5 French. Patients with PICC catheter sizes 5 French and 6 French were found to have an 
earlier onset of VTE than patients with smaller size PICC lines.11 Evans and colleagues found a 
correlation between catheter size and incidence of VTE when progressing from smaller 4 French 
(0.6%) to 5-Fr (2.9%) to larger 6 French (8.8%) PICC lines.6  
Location of vein chosen for PICC insertion has been shown as a contributing factor for 
VTE. Researchers noted PICC lines inserted into the basilic vein were associated with higher 
incidence (3.1%) of VTE than those that are inserted into the cephalic or brachial veins.14 
Location of the catheter insertion has been noted as a predisposing factor to the development of 
VTE. In a retrospective review of 400 cases, those with left-sided catheter insertion were noted 
to be more likely to develop a VTE.5 The authors suggest the longer left innominate vein may be 
the reason for this finding.5 
Mechanically ventilated patients have also been identified at higher risk for VTE due to 
decreased cardiac output particularly in the presence of hypovolemia impaired cardiovascular 
reflexes and/or venous stasis.24, 25 Information on the subjects as it relates to the status of 
mechanical ventilator use was not collected or analyzed. Despite these risk factors, no 
statistically significant difference was noted in the development of VTE between the CHG or 
non-CHG PICC groups. 
Post insertion bleeding 
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 The CHG PICC line has demonstrated anti-thrombogenic properties for up to 30 days in 
clinical testing and post insertion bleeding is a known potential side effect.20 Thirty-three (20%) 
subjects experienced post insertion bleeding. In this study, moderate bleeding requiring the 
application of a thrombogenic dressing occurred more often in subjects with the CHG PICC.  
The findings in this study are similar to another study where post insertion bleeding occurred in 
30% of patients. 22 For the majority of patients the bleeding was resolved by the use of a 
thrombogenic dressing, however, in 6 (18%) instances severe bleeding occurred requiring the 
application of a pressure dressing.  
Limitations 
Limitations of this study include the small sample size and single institution location. The 
lack of statistical significance between groups for CLABSI and VTE could be due to insufficient 
power. Post hoc power analysis showed the study obtained a power of only 48.9 % and that to 
have a study powered sufficiently to find a statistical difference with the infection rate found in 
the study would require a sample size of 348 (174 in each group).  
Blinding of the study was not possible as the catheters differ in appearance and may have 
introduced bias into the study. It is possible that nurses (and patients) may have been more 
conscientious in the care and maintenance of the PICC lines because of their participation in the 
study. Another limitation of the study is that minimal demographic and patient characteristic 
information were collected on the participants. It is possible that there may be have been 
significant differences between the groups despite the use of randomized group assignment. 
Therefore, it is recommended that potential confounders like diagnosis, severity of illness, and 
co-morbidities, be collected in future studies. 
Strengths 
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These limitations notwithstanding, this study had important strengths, such as the study 
design. To our knowledge this is the first RCT examining the effect of CHG impregnated 
antimicrobial PICC lines versus non-CHG PICC lines on the development of CLABSI and/or 
VTE. The inclusion of three high risk units (cardiovascular thoracic, MICU and oncology) with 
diverse patient populations is an additional strength of the study. Lastly, the utilization of a 
dedicated team for insertion, daily assessment and dressing changes of the PICC lines reduced 
the risk of variations in clinical practice techniques. The use of one infection prevention 
specialist for verification of CLABSIs reduced inter-rater reliability in this study. 
CONCLUSION 
 In this study, no difference was noted in CLABSI or VTE between patients who received 
the CHG or non-CHG PICC line. More patients with the CHG PICC line had post insertion 
bleeding requiring the application of a thrombogenic dressing and in some instances a pressure 
dressing. Additional RCT’s with larger samples from multiple acute care hospitals are warranted 
to validate the findings of this study.  
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Figure 1. Study flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*At time of the study, the triple lumen Chlorhexidine PICC was not available. 
Assessed for eligibility (n = 189) 
Excluded (n = 22 ) 
 Length of stay < 48 hours (n = 5) 
 Order discontinued (n = 4) 
 Difficult placing Chlorhexidine PICC (n = 3) 
 PICC placed in interventional radiology (n = 3) 
 Need for triple lumen access (n = 2)* 
 Death prior to PICC placement (n = 2) 
 Request to be withdrawn (n = 1) 
 Emergency placement of PICC (n = 1) 
 Incorrect consent (n = 1) 
Analyzed (n = 80) 
Randomized to Chlorhexidine PICC  
(n = 80) 
 Received Chlorhexidine PICC (n = 80) 
Randomized to non-Chlorhexidine PICC 
(n = 87) 
 Received non-Chlorhexidine PICC  
(n = 87)
Analyzed (n = 87) 
Randomization
Analysis 
Randomized (n = 167)
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Table 1. Comparison of Demographic and Participant Characteristics 
Characteristic Chlorhexidine
PICC 
(n = 80) 
Non-
Chlorhexidine 
PICC 
(n = 87) 
p value 
 N (%) N (%)  
Gender 95 (57) 72 (43) .76 
Study unit 
Medical Intensive Care Unit
Cardiovascular Thoracic Unit
Oncology Unit
 
28 
21 
29 
 
31 
27 
31 
 
 
.71 
PICC type 
5 Fr
Other
 
74 (90.2) 
8 (9.8) 
 
77 (90.6) 
8 (9.4) 
 
1.0 
PICC location  
Basilic vein
Other
 
13 (15.9) 
69 (84.1) 
 
17 (20.0) 
68 (80.0) 
 
.55 
Number of lumens 
Double
Single
 
79 
3 
 
77 
8 
 
.20 
    
 Mdn (IQR) Mdn (IQR)  
Age (years) 62 (22) 64 (21) .42 
Duration of PICC line (days) 8 (8) 8 (8) .86 
 
 
Table 2. Comparison of outcomes by PICC group (N = 167) 
Outcome Chlorhexidine
PICC 
(n = 80) 
Non-Chlorhexidine 
PICC 
(n = 87) 
 
 N (%) N (%) p value 
Central line associated blood stream infection 2 (2.5) 1 (1.1) .067 
Venous thromboembolism 1 (1.3) 2 (2.2) 1.000 
Moderate bleeding requiring use of thrombix 
dressing 
26 (32.5 1 (1.1) < .001 
Severe bleeding requiring pressure dressing 5 (6.3) 1 (1.1) .105 
 
